反応式
Cl.FC1C([C:27]([F:30])([F:29])[F:28])=C(C2CCN(C(C3C4CCNCC=4NN=3)=O)CC2)C=C(F)C=1.BrCCC(F)(F)F.[F:38][C:39]1[C:40]([C:67]([F:70])([F:69])[F:68])=[C:41]([CH:46]2[CH2:51][CH2:50][N:49]([C:52]([C:54]3[C:58]4[CH2:59][N:60]([CH2:63][CH2:64]OC)[CH2:61][CH2:62][C:57]=4[NH:56][N:55]=3)=[O:53])[CH2:48][CH2:47]2)[CH:42]=[C:43]([F:45])[CH:44]=1>>[F:38][C:39]1[C:40]([C:67]([F:70])([F:69])[F:68])=[C:41]([CH:46]2[CH2:51][CH2:50][N:49]([C:52]([C:54]3[C:58]4[CH2:59][N:60]([CH2:63][CH2:64][C:27]([F:30])([F:29])[F:28])[CH2:61][CH2:62][C:57]=4[NH:56][N:55]=3)=[O:53])[CH2:48][CH2:47]2)[CH:42]=[C:43]([F:45])[CH:44]=1参加物
4
反応物 3
生成物 1
実験手順
Following general procedure GP-G2, (4-(3,5-difluoro-2-(trifluoromethyl)phenyl)piperidin-1-yl)(4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridin-3-yl)methanone hydrochloride (60) and 3-bromo-1,1,1-trifluoropropane were converted to (4-(3,5-difluoro-2-(trifluoromethyl)phenyl)piperidin-1-yl)(5-(2-methoxyethyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl)methanone as a white solid (41 mg, 51%): 1H NMR (500 MHz, DMSO-d6) δ 12.83 (m, 1H), 7.43 (m, 2H), 5.12 (m, 1H), 4.67 (m, 1H), 3.53 (m, 2H), 2.50-3.12 (m, 11H), 1.68 (m, 4H); ESI MS m/z 511 [M+H].
出典と根拠
- ORDレコード
- ord-44d0ef14c6674ac0993cc7d2a077f25e
- 出典データセット
- uspto-grants-2016_09
- 特許番号
- US09434727B2
関連ノート
読み込み中…